Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2026-03-30 Capital/Financing Update
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
[기재정정]신규시설투자등
Capital/Financing Update Classification · 65% confidence The document is a public correction notice (“정정신고(보고)”) regarding the timing of a planned new facility investment (Magok new headquarters and R&D center) by the listed company. It provides details of the investment amount, equity ratio, updated investment period, and notes on financing (to be funded via long-term borrowing). This is not a report publication announcement nor a financial statement, but an update on the company’s capital expenditure and financing plan. Thus it fits the “Capital/Financing Update” category.
2026-03-30 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the 20th fiscal year (2025) of Cellid Co., Ltd. It contains comprehensive information including company overview, history, capital changes, business activities, and financial data. In the context of Korean regulatory filings (DART), the 'Business Report' (사업보고서) is the equivalent of an Annual Report (10-K). FY 2025
2026-03-23 Korean
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is titled “감사보고서 제출” (Audit Report Submission) and contains the auditor’s opinion, audit period, audit firm name (삼정회계법인), and key financial figures for the fiscal years 2025 and 2024. It is not a full annual report but a standalone audit report. Therefore, the correct filing category is Audit Report / Information (Code: AR). FY 2025
2026-03-23 Korean
[기재정정]신규시설투자등
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (Cellid) regarding a 'Correction Report' (정정신고) for a 'New Facility Investment' (신규시설투자). It details changes to the investment period end date and provides updated information on the construction project. Since this is a specific regulatory disclosure regarding capital expenditure and investment updates that does not fit into the other specialized categories like M&A or Share Issues, it is classified as a general Regulatory Filing (RNS).
2026-03-11 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Cellid Co., Ltd. It details the meeting date, location, agenda items (such as financial statement approval, director appointments, and articles of association changes), and voting procedures (including electronic voting). This document is a standard proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and request their participation/votes. It fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-03-10 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) for the 20th Annual General Meeting of Cellid. It contains detailed information regarding the meeting agenda, including the approval of financial statements, amendments to the articles of incorporation, and instructions for shareholders to exercise their voting rights via proxy or electronic voting. This document is a standard proxy solicitation material sent to shareholders to request their votes for an upcoming meeting.
2026-03-10 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.